Released | Company | Title | Industry | Topic |
---|---|---|---|---|
01 Oct 2021 08:32 CEST |
IMMUPHARMA | ImmuPharma - EURONEXT DELISTING | 20103010 Biotechnology | Other subject |
30 Sep 2021 12:10 CEST |
IMMUPHARMA | ImmuPharma - PROF. SYLVIANE MULLER AWARDED PRESTIGIOUS ‘LEGION D’HONNEUR’ | 20103010 Biotechnology | Other subject |
29 Sep 2021 09:32 CEST |
IMMUPHARMA | ImmuPharma - Interim Results Announcement | 20103010 Biotechnology | Other subject |
29 Sep 2021 09:30 CEST |
IMMUPHARMA | ImmuPharma - Corporate Update | 20103010 Biotechnology | Corporate life |
30 Jul 2021 08:38 CEST |
IMMUPHARMA | ImmuPharma - Board Changes | 20103010 Biotechnology | Corporate life |
16 Jul 2021 08:56 CEST |
IMMUPHARMA | ImmuPharma - Board Appointment | 20103010 Biotechnology | Corporate life |
28 Jun 2021 14:18 CEST |
IMMUPHARMA | ImmuPharma - 2021 RESULT OF ANNUAL GENERAL MEETING – ALL RESOLUTIONS PASSED | 20103010 Biotechnology | General meeting / Board Meeting |
24 Jun 2021 09:05 CEST |
IMMUPHARMA | ImmuPharma - FDA to agree on the Lupzuor™ PK study via a written response to “Type C” meeting as Avion prepares for international Phase 3 trial | 20103010 Biotechnology | Products and services |
02 Jun 2021 09:24 CEST |
IMMUPHARMA | ImmuPharma - Notice of AGM and posting of Report & Accounts | 20103010 Biotechnology | General meeting / Board Meeting |
24 May 2021 09:40 CEST |
IMMUPHARMA | ImmuPharma - Director Retirement | 20103010 Biotechnology | Corporate life |
29 Apr 2021 09:17 CEST |
IMMUPHARMA | ImmuPharma - Final Result Announcement | 20103010 Biotechnology | Other subject |
09 Feb 2021 08:48 CET |
IMMUPHARMA | ImmuPharma - Lupuzor™ scheduled to commence international Phase 3 trial in Lupus patients in H2 2021 | 20103010 Biotechnology | Products and services |
18 Jan 2021 10:24 CET |
IMMUPHARMA | ImmuPharma - Appointment of Company Secretary | 20103010 Biotechnology | Corporate life |
04 Jan 2021 08:55 CET |
IMMUPHARMA | ImmuPharma - Lanstead TR1 | 20103010 Biotechnology | Change in Capital |
02 Dec 2020 14:59 CET |
IMMUPHARMA | IMMUPHARMA TO PRESENT AT BIOTECH SHOWCASE™ DIGITAL 2021 | 20103010 Biotechnology | Other subject |
26 Nov 2020 08:27 CET |
IMMUPHARMA | ImmuPharma - Grant of Share Options & PDMR dealing | 20103010 Biotechnology | Other subject |
23 Nov 2020 08:43 CET |
IMMUPHARMA | ImmuPharma - Conversion of Convertible Security | 20103010 Biotechnology | Change in Capital |
20 Nov 2020 09:21 CET |
IMMUPHARMA | ImmuPharma - FDA confirms 4 December 2020 for Type ‘A’ meeting to discuss guidance on forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients | 20103010 Biotechnology | Products and services |
10 Nov 2020 08:55 CET |
IMMUPHARMA | IMMUPHARMA - Update on submission to the FDA for the forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients | 20103010 Biotechnology | Products and services |
30 Sep 2020 08:54 CEST |
IMMUPHARMA | ImmuPharma - Interim results for the six months ended 30 June 2020 | 20103010 Biotechnology | Other subject |
30 Sep 2020 08:52 CEST |
IMMUPHARMA | ImmuPharma - Total Share Capital Notification - Admission to trading on Euronext Growth Brussels of newly issued ordinary shares | 20103010 Biotechnology | Change in Capital |
29 Sep 2020 09:16 CEST |
IMMUPHARMA | ImmuPharma - Share Subscription into Incanthera plc | 20103010 Biotechnology | Other subject |
22 Sep 2020 08:46 CEST |
IMMUPHARMA | ImmuPharma - Repayment of Convertible Security | 20103010 Biotechnology | Change in Capital |
11 Sep 2020 10:48 CEST |
IMMUPHARMA | ImmuPharma - Update on submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients | 20103010 Biotechnology | Products and services |
10 Sep 2020 13:27 CEST |
IMMUPHARMA | ImmuPharma - Conversion of Convertible Security | 20103010 Biotechnology | Change in Capital |
09 Sep 2020 16:50 CEST |
IMMUPHARMA | ImmuPharma - Conversion of Convertible Security | 20103010 Biotechnology | Change in Capital |
07 Sep 2020 08:45 CEST |
IMMUPHARMA | ImmuPhartma - Placing to raise £6.5 million – update ; related party transaction | 20103010 Biotechnology | Change in Capital |
03 Sep 2020 09:07 CEST |
IMMUPHARMA | ImmuPharma - Conversion of Convertible Security | 20103010 Biotechnology | Change in Capital |
02 Sep 2020 08:31 CEST |
IMMUPHARMA | ImmuPharma - Placing to raise £6.5 million | 20103010 Biotechnology | Change in Capital |
27 Jul 2020 09:27 CEST |
IMMUPHARMA | ImmuPharma - Submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients | 20103010 Biotechnology | Other subject |
11 Jun 2020 08:40 CEST |
IMMUPHARMA | STRATEGIC INVESTMENTS FROM TWO SPECIALIST US HEALTHCARE INVESTORS | 20103010 Biotechnology | Other subject |
05 Jun 2020 08:50 CEST |
IMMUPHARMA | Notification of Change of Registered Office Address | 20103010 Biotechnology | Other subject |
02 Jun 2020 11:13 CEST |
IMMUPHARMA | Notification of Change of AGM Venue | 20103010 Biotechnology | General meeting / Board Meeting |
21 May 2020 09:18 CEST |
IMMUPHARMA | Notice of AGM and posting of Report & Accounts | Biotechnology | General meeting / Board Meeting |
14 May 2020 08:45 CEST |
IMMUPHARMA | ImmuPharma’s efforts in the fight against Covid-19 with Lupuzor™ and Ureka | Biotechnology | Products and services |
30 Apr 2020 11:13 CEST |
IMMUPHARMA | ImmuPharma - Audited Report & Accounts published on website | Biotechnology | Other subject |
30 Apr 2020 08:18 CEST |
IMMUPHARMA | ImmuPharma - FINAL RESULTS ANNOUNCEMENT for the twelve months ended 31 December 2019 | Biotechnology | Other subject |
06 Apr 2020 09:37 CEST |
IMMUPHARMA | ImmuPharma to present live on ‘Investor Meet Company’ platform | Biotechnology | Meetings / events |
30 Mar 2020 09:19 CEST |
IMMUPHARMA | Erratum - Subscription to raise £1.5 million to fund expansion of R&D pipeline | Biotechnology | Other financial transaction |
30 Mar 2020 08:11 CEST |
IMMUPHARMA | Subscription to raise £1.5 million To fund expansion of R&D pipeline | Biotechnology | Other financial transaction |
28 Feb 2020 10:02 CET |
IMMUPHARMA | Incanthera plc – Admission to trading on the NEX Exchange Growth Market Publication of Admission Document | Biotechnology | Other subject |
17 Feb 2020 09:55 CET |
IMMUPHARMA | Oncology specialist Incanthera, in which ImmuPharma currently has a 14.0% shareholding, announces Rule 23 Notice in advance to quoting on NEX Exchange Growth Market | Biotechnology | Other financial transaction |
06 Feb 2020 08:16 CET |
IMMUPHARMA | ImmuPharma provides an update on the Avion Agreement in relation to Lupuzor™’s new international Phase III trial | Biotechnology | Other subject |